Feasibility randomised controlled trial: probiotics and milk formula to prevent allergic disease
| ISRCTN | ISRCTN00424386 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN00424386 |
| Protocol serial number | CZG/2/277 |
| Sponsor | Chief Scientist Office (UK) |
| Funder | Chief Scientist Office (UK) (ref: CZG/2/277) |
- Submission date
- 13/02/2008
- Registration date
- 27/02/2008
- Last edited
- 10/04/2012
- Recruitment status
- Stopped
- Overall study status
- Stopped
- Condition category
- Signs and Symptoms
Plain English summary of protocol
Not provided at time of registration
Contact information
Scientific
Division of Community Health Sciences: GP Section
The University of Edinburgh
Levinson House
20 West Richmond Street
Edinburgh
EH8 9DX
United Kingdom
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Feasibility study: 2 x 2 factorial randomised controlled design |
| Secondary study design | Randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | Investigating the effectiveness of primary prevention strategies using extensively hydrolysed milk formula and probiotic supplements to prevent allergic disease in high risk infants: pilot factorial randomised controlled trial |
| Study objectives | The primary aim of this pilot study is to test the feasibility of administering an extensively hydrolysed milk formula, with either a placebo probiotic or probiotic, to mothers with infants at high risk of atopic disease in Scotland and compare the likely uptake and effectiveness of these interventions using a factorial randomised controlled trial. This study will inform a definitive large-scale multi-centre double blind placebo randomised controlled trial. As of 10/04/2012, the anticipated end date of trial was updated from 31/12/2008 to 31/10/2008. |
| Ethics approval(s) | Ethics approval pending from the Lothian Ethics Committee as of 13/02/2008. |
| Health condition(s) or problem(s) studied | Atopic disease: asthma, atopic dermatitis, allergic rhinitis or food allergy |
| Intervention | 1. Probiotic or placebo probiotic: one sachet of probiotic to be mixed with 1 ml of water, taken once daily 2. Normal milk formula or extensively hydrolysed milk formula: study formula to be taken as needed The total duration of treatment will be six months, and the total duration of follow-up for all treatment arms will be six months. The three and six month assessments will take up to one hour. |
| Intervention type | Drug |
| Phase | Not Specified |
| Drug / device / biological / vaccine name(s) | Milk formula, probiotic |
| Primary outcome measure(s) |
1. Recruitment rate, i.e., what proportion of those invited agree to participate, measured at three months |
| Key secondary outcome measure(s) |
Not provided at time of registration. |
| Completion date | 31/10/2008 |
| Reason abandoned (if study stopped) | "Objectives no longer viable" |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Child |
| Sex | All |
| Target sample size at registration | 36 |
| Key inclusion criteria | 1. Infants at high risk of atopy as judged by the mother, father or sibling having an allergic disease (asthma, allergic rhinitis, atopic dermatitis and food allergy) 2. Booked to give birth at the Royal Infirmary, Edinburgh |
| Key exclusion criteria | 1. Do not give informed consent 2. Multiple pregnancy 3. Delivering prior to 37 weeks gestation |
| Date of first enrolment | 01/04/2008 |
| Date of final enrolment | 31/10/2008 |
Locations
Countries of recruitment
- United Kingdom
- Scotland
Study participating centre
EH8 9DX
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |